Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by priceless2on Feb 10, 2020 10:09am

191 Views

Post# 30667220

Eli Lilly and failed Alzheimer drug

I wonder if now Eli Lilly will be more interested in doing a deal with RVX now that their Alzheimer drug failed, RVX also has some synergistic effect that Apabetalone has with the ani diabetic treatment SGLT2i that lilly has a drug for ...... My Guess for a deal is either Lilly , Pfizer , or Boehringer Ingelheim or Merck, They are the BP"s that have the most to gain from the current RVX pipeline and now that RVX has a Breakthrough Therapy designation it makes sense to do some type of deal to lock up the IP from competitors IMO

https://www.nasdaq.com/articles/lilly-and-biogen-stocks-get-hit-as-another-alzheimers-treatment-fails-a-trial-2020-02-10

Bullboard Posts

High Tide adds two stores to undervalued cannabis retail network